Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum SPDR S&P Bank ETF KBE

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Banks Select Industry Index. The fund generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index tracks the performance of publicly traded national money centers and leading regional banks. It may invest in equity securities that are not included in the index, cash and cash equivale...

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{currentVideo.storiesTitle}}:
{{story.companySymbol}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

  rate and reply

FSD Pharma Files Investigational New Drug Application “IND”

   rate and reply

FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets

  rate and reply

Lucid-MS for Multiple Sclerosis Treatment

  rate and reply

"Julia Levy Award" Recipient David Allan and Dr. John McGraw

   rate and reply

FSD Pharma Inc: Lucid MS Video

FSD Pharma is delighted to announce pre-clinical findings...read more

FSD: Cancellation of Certain Shares Issued to Former CEO

FSD Pharma Announces Cancellation of Certain Shares Issued to Former Chief Executive Officer Dr. Raza Bokhari   TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA...read more

FSD Pharma Issues Corporate Updates

FSD Pharma Issues Corporate Updates TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to...read more

iMining: First Hospital Foundation in Decentraland Metaverse

iMining Enters into Agreement for the First-Ever Hospital Foundation to Be Launched in the Decentraland Metaverse   Vancouver, British Columbia--(Newsfile Corp.) - iMining Technologies Inc...read more

FSD Pharma; Recapping 2021 and What to Look Forward in 2022

  rate and reply

FSD Pharma Inc: Lucid MS Video

FSD Pharma is pleased to share pre-clinical data demonstrating the effectiveness of its lead drug candidate, Lucid-MS, in treating Multiple Sclerosis. The unique potential therapeutic value of Lucid...read more